BioSpace News Archive

First patient dosed in the phase I small cell lung cancer (SCLC) trial with Debio 1124, a molecular-targeted radiotherapy

American Manufacturer will supply the state of Illinois Dept. of Human Services with millions of FDA registered (ASTM Level 2) surgical masks.

Cambridge Blockchain announced a new partnership with Zensark today. The partnership enables Cambridge Blockchain’s Tracelinks to offer an AI-powered cough analyzer through Zensark’s Swaasa service. “Respiratory symptoms are among the top 5 most common symptoms for COVID-19 patients. Having an app available for in-home cough analysis opens up new possibilities and helps employers to use additional measures to k

VBI Vaccines Announces Preclinical Coronavirus Program Data and Selection of Clinical Candidates with Potential as One-Dose Vaccines - VBI-2901 and VBI-2902 selected as trivalent and monovalent coronavirus vaccine candidates, respectively, for an adaptive Phase 1/2 clinical study expected to begin around year-end 2020, subject to regulatory approvals - After one dose, compared to high-titer convalescent sera, preclinical data demonstrated 10x higher anti

SurGenTec, a privately held spine and orthopedic technology company, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary OsteoFlo NanoPutty- Quadphasic Synthetic Bone Graft. OsteoFlo NanoPutty is a novel bone graft solution featuring the world’s first, and only quadphasic synthetic bone graft particles with nano-surface technology. OsteoFlo NanoPutty h

Propeller Health today announced it will begin distributing in Japan, via a collaboration with Novartis to connect the Propeller digital health platform to Enerzair® and Atectura® Breezhaler®, two new once-daily Novartis medications available outside the U.S. to treat uncontrolled asthma.

TYME-19 is an oral synthetic bile acid that has demonstrated broad spectrum antiviral activity as well as efficacy against COVID-19 in preclinical studies Initiating proof-of-concept RESPOnD trial to investigate TYME-19 for safety and efficacy in recently diagnosed, symptomatic COVID-19 patients RESPOnD trial is being led in collaboration with investigators from Massachusetts General Hospital and Weill Cornell Medical Center Trial is ta

- Primary Endpoints Met in PSOARING 1 and PSOARING 2 Clinical Trials (P-values <0.0001) - - Up to 80% of Patients Achieved ≥1-Grade Improvement in PGA - - All Secondary Endpoints Achieved in Both Trials, Including PASI75 - - Tapinarof is a Potential First-in-Class Psoriasis Treatment with a Novel Mechanism of Action - - To Date, Over 2,200 Subjects Have Enrolled in 17 Clinical Trials of Tapinarof

AllStar Health Brands Inc. (OTC PINK:ALST) a specialty pharmaceutical and nutritional supplements company and TPT Global Tech a technology and solutions company are pleased to announce signing a Non Exclusive Distribution Agreement for Canada and US to add to the existing Non-Exclusive Distribution Agreement for Mexico and other Latin American countries.

electroCore Inc, (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced that it will be presenting at the LD 500 investor conference on Thursday, September 3rd at 6:20 AM PST / 9:20 AM EST. Dan Goldberger, Chief Executive Officer of electroCore, will be presenting to a live audience.